To include your compound in the COVID-19 Resource Center, submit it here.

DiaPep277: Development discontinued

Hyperion is discontinuing DiaPep277 after discovering research misconduct in development of the Type I diabetes product by employees of Hyperion's Andromeda Biotech Ltd. subsidiary. Hyperion said it

Read the full 274 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE